Stockscreener 앱 받기
42.35
0.88%
0.37
시간 외 거래:
41.90
-0.45
-1.06%
전일 마감가:
$41.98
열려 있는:
$41.98
하루 거래량:
582.28K
Relative Volume:
0.84
시가총액:
$2.31B
수익:
$1.28B
순이익/손실:
$-222.15M
주가수익비율:
-10.35
EPS:
-4.09
순현금흐름:
$145.52M
1주 성능:
-3.68%
1개월 성능:
-6.94%
6개월 성능:
-13.94%
1년 성능:
-19.96%
1일 변동 폭
$41.98
$42.56
1주일 범위
$41.94
$44.63
52주 변동 폭
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
명칭
Livanova Plc
전화
4402033250662
주소
20 EASTBOURNE TERRACE, LONDON
LIVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
42.35 | 2.40B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-20 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | 개시 | Goldman | Buy |
| 2024-09-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | 재확인 | Needham | Buy |
| 2024-02-20 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Hold |
| 2023-07-19 | 개시 | Robert W. Baird | Neutral |
| 2023-04-14 | 개시 | Mizuho | Neutral |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-02-24 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-03 | 개시 | Goldman | Buy |
| 2021-08-20 | 재확인 | Needham | Buy |
| 2021-07-20 | 업그레이드 | Needham | Hold → Buy |
| 2021-03-03 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-01-05 | 다운그레이드 | Needham | Buy → Hold |
| 2020-09-02 | 개시 | Robert W. Baird | Outperform |
| 2020-06-26 | 재확인 | Needham | Buy |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-02-28 | 재확인 | Needham | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-08-02 | 재확인 | Needham | Buy |
| 2018-06-08 | 개시 | Stifel | Buy |
| 2018-05-31 | 재확인 | Needham | Buy |
| 2018-02-28 | 재확인 | Needham | Buy |
모두보기
Livanova Plc 주식(LIVN)의 최신 뉴스
Wearable Cardioverter Defibrillators Market is projected - openPR.com
What analysts say about LivaNova PLC stockDouble-digit growth - Autocar Professional
Is LivaNova PLC a good long term investmentFree Stock Market Beginners Guide - jammulinksnews.com
LivaNova PLC Stock Analysis and ForecastOutstanding investment returns - Jammu Links News
Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT - MSN
What drives LivaNova PLC stock priceDouble-digit growth - jammulinksnews.com
Neuro Modulation Devices Market is expected to reach US$ 7.6 - openPR.com
(LIVN) Technical Data - news.stocktradersdaily.com
‘A vicious life loop’: Epilepsy community calls for action to address the burden of disease - medianet.com.au
Principal Financial Group Inc. Purchases 3,668 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
10 Undervalued Medical Device Stocks to Buy Now - Insider Monkey
How LivaNova PLC stock performs during market volatilityStable Stocks With High Yield - Newser
Why LivaNova PLC stock attracts strong analyst attentionInsider Strategy Insight - Newser
Vagus Nerve Stimulators Market Exclusive Report with Detailed - openPR.com
LivaNova to Announce Second-Quarter 2025 Results | LIVN Stock Ne - GuruFocus
LivaNova to Announce Second-Quarter 2025 Results - Business Wire
LivaNova: The Sell-Off Is Excessive Here (NASDAQ:LIVN) - Seeking Alpha
Here's Why LivaNova (NASDAQ:LIVN) Can Manage Its Debt Responsibly - 富途牛牛
LivaNova PLC (LIVN): A High-Conviction Buy at Oversold Levels - AInvest
Trading (LIVN) With Integrated Risk Controls - news.stocktradersdaily.com
LivaNova PLC(NasdaqGS: LIVN) dropped from Russell 2000 Growth Index - MarketScreener
LivaNova PLC(NasdaqGS: LIVN) dropped from Russell 2000 Growth-Defensive Index - MarketScreener
Are Options Traders Betting on a Big Move in LivaNova Stock? - Nasdaq
Latest Developments and Regulatory Approvals - openPR.com
LivaNova Announces CORE-VNS 24-Month Data - Medical Product Outsourcing
Global Neuromodulation Market to grow at a CAGR of 8.95% by 2030, - openPR.com
Global Neuromodulation Market to grow at a CAGR of 8.95% by 2030, Evaluates DelveInsight | Medtronic, Abbott, Boston Scientific Corp, LivaNova, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc - Barchart.com
Global Neurostimulation Devices Market to grow at a CAGR - openPR.com
(LIVN) Investment Report - news.stocktradersdaily.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com Nigeria
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles - Investing.com
Wearable Cardioverter Defibrillators (WCD) Market Growth | - openPR.com
LivaNova Shareholders Approve New Incentive Plans - Investing.com
LivaNova Shareholders Approve New Incentive Plans By Investing.com - Investing.com Canada
LivaNova Shareholders Approve Key Incentive Plans at AGM - TipRanks
Livanova petitions CMS to drop CED mandate for VNS for depression - BioWorld MedTech
LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network
LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com South Africa
VNS therapy shows sustained seizure reduction in study By Investing.com - Investing.com South Africa
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace
Livanova Plc (LIVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
0.17%
자본화:
|
볼륨(24시간):